

1 FW

A circular black and white stamp. The outer ring contains the text "OIPE" at the top and "OFFICE OF INTELLECTUAL PROPERTY" at the bottom. The center of the stamp contains the date "DEC 27 2004".

Art Unit: 1614

Filed: July 23, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Signature

Dec. 21, 2004
Silvia Congleton

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- 1-

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,




Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626
Aventis Docket No. **DEAV2002/0051 US NP**

☒

+

Substitute for form 1449A/PTO



(use as many sheets as necessary)

Sheet

1

C

3

Application Number	10/625,085
Filing Date	07-23-2003
First Named Inventor	GRATZER
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	DEAV2002/0051 - US - NP

[illegible][illegible]

Date	
Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/625,085
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	07-23-2003
		First Named Inventor	GRATZER
		Group Art Unit	1614
		Examiner Name	Unknown
		Attorney Docket Number	DEAV2002/0051 - US - NP
Sheet	2	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		A.J. BROWN et al., Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein alpha-subunit chimeras, Yeast, Vol. 16, 2000, pp. 11-22	
		B.R. CONKLIN et al., Substitution of three amino acids switches receptor specificity of Gqalpha to that G1alpha, Nature, Vol. 363, 1993, pp. 274-276	
		D. MUMBERG et al., Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds, Gene, Vol. 156, 1995, pp. 119-122	
		E.M. KAJKOWSKI et al., Investigation of Growth Hormone Releasing Hormone Receptor Structure An Activity of Using Yeast Expression Technologies, J. of Receptor & Signal Transduction Research, Vol. 17, 1997, pp. 293-303	
		L.A. PRICE et al., Functional Coupling of a Mammalian Somatostatin Receptor to the Yeast Pheromone Response Pathway, Molecular and Cellular Biology, Vol. 15, No. 11, Nov. 1995, pp. 6188-6195	
		L.A. PRICE et al., Pharmacological Characterization of the Rat A2a Adenosine Receptor Functionally Coupled to the Yeast Pheromone Response Pathway, Molecular Pharmacology, Vol. 50, 1996, pp. 829-837	
		M. CISMOWSKI et al., Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling, Nature Biotechnology, Vol. 17, Sept. 1999, pp. 878-883	
		M.H. PAUSCH, G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery, Trends in Biotechnology, Vol. 15, No. 12, Dec. 1997, pp. 487-494	
		N. ANCELLIN et al., Differential Pharmacological Properties and Signal Transduction of the Sphingosine 1-Phosphate Receptors EDG-1, EDG-3 and EDG-5, Journ. of Biological Chemistry, Vol. 274, No. 27, Jul 2, 1999, pp. 18997-19002	
		R.M. CAMPBELL et al., Selective A1-Adenosine Receptor Antagonists Identified Using Yeast Saccharomyces Cerevisiae Functional Assays, Bioorganic & Medicinal Chemistry Letters Vol. 9, 1999, pp. 2413-2418	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/625,085	
			Filing Date	07-23-2003	
			First Named Inventor	GRATZER	
			Group Art Unit	1614	
			Examiner Name	Unknow	
Sheet	3	of	3	Attorney Docket Number	DEAV2002/0051 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		R.M. FREDRICKSON, Budding actors in mammalian G-protein signaling, Nature Biotechnology, Vol. 17, Sept. 1999, pp. 852-853	
		NM 000623	
		NM 000738	
		NM 000740	
		NM 001050	
		NM 001400	
		NM 004230	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.